Short Interest in Vincerx Pharma, Inc. (NASDAQ:VINC) Decreases By 59.7%

Vincerx Pharma, Inc. (NASDAQ:VINC) was the target of a significant drop in short interest in February. As of February 15th, there was short interest totalling 108,500 shares, a drop of 59.7% from the January 31st total of 269,200 shares. Based on an average trading volume of 711,500 shares, the days-to-cover ratio is currently 0.2 days. Approximately 5.7% of the company’s stock are sold short.

Vincerx Pharma Stock Performance

Shares of VINC stock opened at $1.09 on Friday. The firm has a market capitalization of $2.44 million, a price-to-earnings ratio of -0.05 and a beta of 1.38. The stock’s 50-day simple moving average is $2.56 and its 200-day simple moving average is $7.16. Vincerx Pharma has a fifty-two week low of $1.05 and a fifty-two week high of $187.44.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.